Clinical Trials

1 2 3 4 5 219
Number of results: 4372

PDF print is not allowed for data more than 300.Please search above for fewer data.

Date Product Disease Phase Company Therapeutic area
2018-09-26 CSTD002-NK (adoptive NK cell therapy) reduction of relapse in high risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT) 2 Cytosen Therapeutics (USA - TX) Cancer - Oncology
2018-09-25 Imfinzi® (durvalumab) (MEDI4736) non-small cell lung cancer (NSCLC) 3 AstraZeneca (UK) Cancer - Oncology
2018-09-25 MVX-ONCO-1 head and neck squamous cell carcinoma (HNSCC) 2 Maxivax (Switzerland) Cancer - Oncology
2018-09-24 AKCEA-APO(a)-LRx patients with hyperlipoproteinemia(a) and established cardiovascular disease. 2b Akcea Therapeutics (USA - MA), a subsidiary of Ionis Pharmaceuticals (USA - CA) Cardiovascular diseases - Metabolic diseases
2018-09-24 myvacTM solid tumors preclinical Transgene (France) Cancer - Oncology
2018-09-21 esketamine treatment-resistant depression 3 J&J company (USA - NJ) CNS diseases - Mental diseases
2018-09-20 THR-687 diabetic macular edema 1 Onxurion (Belgium) Ophtalmological diseases
2018-09-20 THR-317 macular telangiectasia type 1 (MacTel 1) 2 Oxurion (Belgium) Rare diseases - Ophtalmological diseases
2018-09-19 MTL-CEBPA advanced liver cancer 1 Mina Therapeutics (UK) Cancer - Oncology
2018-09-15 dupilumab moderate-to-severe atopic dermatitis 3 Sanofi (France) Regeneron Pharmaceuticals (USA - NY) Autoimmune diseases - Dermatological diseases
2018-09-14 Botox® (onabotulinumtoxinA) moderate to severe glabellar lines Allergan (Ireland) Aesthetic medicine
2018-09-14 patisiran transthyretin-mediated amyloidosis (ATTR) - familial amyloidotic polyneuropathy (FAP) 3 Alnylam Therapeutics (USA - MA) Rare diseases - Genetic diseases
2018-09-13 MOR106 atopic dermatitis 1 Galapagos (Belgium) Morphosys (Germany) Autoimmune diseases - Dermatological diseases
2018-09-12 durvalumab (Imfinzi®) and IPH5401 solid tumors, including non small-cell lung cancer (NSCLC) with secondary resistance to prior immuno-oncology (IO) treatment and IO-naïve hepatocarcinoma (HCC) 1-2 Innate Pharma (France) MedImmune (USA - global biologics arm of AstraZeneca (UK) Cancer - Oncology
2018-09-10 FPA144 (bemarituzumab) in combination with mFOLFOX6 previously untreated, advanced gastric or gastroesophageal cancer 1-3 Five Prime Therapeutics (USA - CA) Cancer - Oncology
2018-09-10 Taltz® (ixekizumab) and Tremfya® (guselkumab) moderate to severe chronic plaque psoriasis 4 Eli Lilly (USA - IN) Autoimmune diseases - Dermatological diseases
2018-09-10 sapacitabin and olaparib BRCA mutant breast cancer 1b-2 Cyclacel Pharmaceuticals (USA - NJ) Cancer - Oncology
2018-09-07 COM701 1 Compugen (Israel) Cancer - Oncology
2018-09-05 SB-913 (adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene) mucopolysaccharidosis type II (MPSII - Hunter's syndrome) 1-2 Sangamo Therapeutics (USA - CA) Rare diseases - Genetic diseases
2018-09-05 CYAD-01 - NKR-2 (NKG2D CAR T-Cell) colorectal cancer, ovarian Cancer, urothelial carcinoma, triple-negative breast cancer, pancreatic cancer, acute myeloid leukemia/myelodysplastic syndrome, multiple myeloma 1b Celyad (Belgium) Cancer - Oncology